Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Nanoform Finland

0.91 EUR-2.27 %11.9. klo 18.29
3,783 following

NANOFH

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
-2.27 %
-11.87 %
+9.16 %
+35.02 %
-22.70 %
+5.47 %
-55.59 %
-88.43 %
-82.06 %

Nanoform Finland operates in the medical technology sector. The company specializes in research and development of nanoparticle technology used to create nanoparticles in pharmaceuticals. The technology is used as a complement in the production process and is used for the treatment of diseases such as ALS and Alzheimer's. Customers consist of players in the global pharmaceutical industry, with the largest operations in the Nordic market. Nanoform Finland is headquartered in Helsinki.

Read more
Market cap
77.69M EUR
Turnover
26.52K EUR
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
I will ramble a bit again about Nanoform’s peers regarding subcutaneous bioformulations. Nanoform’s latest interim report slides contain a list of these competing companies and their target molecules. Two names on that list jump out: Halozyme and Alteogen. Halozyme currently has ...
18 hours ago
by jerej
9
Setting up that GMP line at a CDMO facility certainly makes sense. Biological compounds in aqueous solutions generally require cold chain storage. Therefore, locating production and nanoformulation in the same facilities reduces issues related to storage and transport. I browsed ...
8/20/2026, 6:47 AM
by jerej
9
Agreed. Sounds pretty good. Here are more details from the report. “To obtain sterile GMP status for our biological technology, we have initiated discussions with several CDMO organizations regarding the potential placement of our technology in one of their existing facilities. The...
8/20/2026, 5:45 AM
by Latupuikko
9
This is probably a major factor in the recent price action of this stock and similar ones. Nanoform seems to be in a situation where funds are dumping the stock for whatever reason, and the buyer side is missing because it’s such a hard company to grasp. Selling saunas is easier ...
15 hours ago
by jerej
7
This is a strategically sound choice in this situation. A report with no surprises. Things are proceeding as expected and the cost-cutting measures have been effective. There are already so many prospects here that I would argue the cash position is sufficient to get us across the...
8/20/2026, 5:41 AM
5
Nanoform small is powerful Nanoform Q2 2026 - Positive feedback from scientific advice meeting in the... Nanoform Finland Plc | Company Release | August 20, 2026… Nanoenzalutamide project continues with the communicated multitrack strategy supported by all partners. After a positive...
8/20/2026, 5:25 AM
by Latupuikko
5
In my opinion, comparing these risky growth companies based on their current price doesn’t make sense. Nano’s market cap in the spring was under 40 million. Today it’s around 80 million, and on Thursday, it will likely be somewhere completely different. The additional potential brought...
8/18/2026, 10:29 AM
by Latupuikko
5
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
11.11.
2026

Interim report Q3'26

25.2.
2027

Annual report '26

Regulatory press release20.08.2026 klo 08.10

Nanoform Q2 2026 - Positive feedback from scientific advice meeting in the UK, significantly improved cash flow and discussions with CDMOs on sterile GMP for our Biologics technology initiated

Nanoform Finland
Press release06.08.2026 klo 11.00

Invitation to Nanoform’s Q2 2026 Report Presentation

Nanoform Finland
Regulatory press release05.08.2026 klo 12.00

Inside information: Positive Feedback from UK MHRA Scientific Advice Meeting regarding Nanoenzalutamide

Nanoform Finland

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release10.06.2026 klo 13.30

Nanoform Finland Plc – Manager’s Transactions – Jeanne Thoma

Nanoform Finland
Regulatory press release10.06.2026 klo 13.30

Nanoform Finland Plc – Manager’s Transactions – Miguel Calado

Nanoform Finland
Regulatory press release10.06.2026 klo 08.30

Share subscriptions based on the resolution by Nanoform Finland Plc’s Annual General Meeting 2026 on remuneration of the Board of Directors

Nanoform Finland
Regulatory press release29.05.2026 klo 19.10

The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key individuals

Nanoform Finland
Regulatory press release19.05.2026 klo 08.10

Nanoform Q1 2026 report - Record first quarter revenue, income and gross margin, first exclusivity deal signed around our Biologics technology

Nanoform Finland
Regulatory press release12.05.2026 klo 08.00

Inside information: Nanoform Signs First Exclusivity Agreement for Ultra-High Concentration Subcutaneous Delivery

Nanoform Finland
Press release05.05.2026 klo 11.00

Invitation to Nanoform’s Q1 2026 Report Presentation

Nanoform Finland
Regulatory press release21.04.2026 klo 12.20

Resolutions of Nanoform Finland Plc's Annual General Meeting on April 21, 2026

Nanoform Finland
Regulatory press release21.04.2026 klo 12.20

Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland Plc

Nanoform Finland
Regulatory press release02.04.2026 klo 09.30

Nanoform Finland Plc – Manager’s Transactions – Peter Hänninen

Nanoform Finland
Regulatory press release02.04.2026 klo 09.30

Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström

Nanoform Finland
Regulatory press release30.03.2026 klo 21.10

Inside information: Feedback from European Scientific Advice Meeting with Reference Member State Will Delay Submission of European Marketing Authorization Application Planned Initially for May 2026

Nanoform Finland
Regulatory press release19.03.2026 klo 20.00

Notice to the Annual General Meeting of NANOFORM FINLAND Plc

Nanoform Finland
Regulatory press release02.03.2026 klo 16.00

Nanoform Finland Plc – Manager’s Transactions – David Rowe

Nanoform Finland
Regulatory press release02.03.2026 klo 16.00

Nanoform Finland Plc – Manager’s Transactions – Peter Hänninen

Nanoform Finland
Regulatory press release02.03.2026 klo 16.00

Nanoform Finland Plc – Manager’s Transactions – Christian Jones

Nanoform Finland
Regulatory press release02.03.2026 klo 16.00

Nanoform Finland Plc – Manager’s Transactions – Edward Hæggström

Nanoform Finland